Tolvaptan and its potential in the treatment of hyponatremia

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1149-1155

  Dixon, Megan B ^a   Lien, Y Howard ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Arginine vasopressin; Congestive heart failure; Hyponatremia; Liver cirrhosis; Syndrome of inappropriate antidiuretic hormone; Vasopressin receptors

Indexed keywords

AMIODARONE; ARGIPRESSIN; CONIVAPTAN; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; PLACEBO; TOLVAPTAN;

ANTIDIURESIS; AREA UNDER THE CURVE; ARTERIAL PRESSURE; BODY WEIGHT; CARDIOVASCULAR EFFECT; CENTRAL PONTINE MYELINOLYSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; HYPOTENSION; KIDNEY FAILURE; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSMOTIC PRESSURE; POLYDIPSIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE OSMOLALITY; VASOPRESSIN RELEASE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 61549124445     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. 2005. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol, 290:F273-8.
2. Ghali JK, Koren MJ, Taylor JR, et al. 2006. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolernic hyponatremia. J Clin Endocrinol Metab, 91:2145-52.
3. Gheorghaide M, Gattis WA, O'Connor CM, et al. 2004. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA, 291:1963-71.
4. Gheorghiade M, Gottlieb SS, Udelson JE, et al. 2006. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatement of hyponatremia. Am J Cardiol, 97:1064-7.
5. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. 2007. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA, 297:1332-43.
6. Gheorghaide M, Niazi I, Ouyang J, et al. 2003. Vasopressin V2-receptor blockage with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation, 107:2690-6.
7. Goldsmith SR. 2007. Is there a cardiovascular rational for the use of combined V1A/V2 receptor antagonists? Am J Med, 119(Suppl 7A):S93-6.
8. Goldsmith SR, Francis GS, Cowley AW Jr, et al. 1983. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol, 1:1385-90.
9. Konstam MA, Gheorgaide M, Burnett JC Jr, et al. 2007. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA, 297:1319-31.
10. Lee DS, Austin PC, Rouleau JL, et al. 2003. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA, 290:2581-7.
11. Lien YH, Shapiro JI. 2007. Hyponatremia: clinical diagnosis and management. Am J Med, 120:653-8.
12. Schrier RW 2007. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med, 119(Suppl 7A): S47-53.
13. Schrier RW, Gross P, Gheorghiade M, et al. 2006. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med, 355:2099-112.
14. Shoaf SE, Elizari MV, Wang Z, et al. 2005. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther, 10:165-71.
15. Shoaf SE, Graumer SL, Bricmont P, et al. 2007. Pharmacokinetic and harmacodynamic interaction between tolvaptan, an ono-peptide AV antagonist and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol, 50:213-2.
16. Udelson JE, McGrew FA, Flores E, et al. 2005. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function inpatient with heart failure and systolic dysfunction. J Am Coll Cardiol, 49:2151-9.